b'LabPMM Assay GuidelinesMyAML is a targeted gene panel that analyzes the coding and non-coding exons of nearly 200 genes, as well as the breakpoint hotspots within 36 genes. MyAML combines long read chemistry and deep sequencing with an optimized and validated custom bioinformatics pipeline, MyInformatics, to specifically examine genomic variants in AML patients . Consider testing with MyAML as an entry point into clinical trials or to optimize treatment NPM1 Patient with suspected or FLT3 or LeukoStratCDx FLT3 Mutation Assay confirmed AML diagnosisOur FLT3 ITD and NPM1 MRD testsFollow-up with MRD assays unique for biomarkers are amplicon-based NGS assays,identified in each patient, such as FLT3 ITD MRD, with a limit of detection of 5x10 -5 NPM1 MRD and MyMRD MyAML and MyMRD are CLIA validated assays.54'